

INTRO

We welcome the year 2023 which is a very exiting year for Cessatech, we are expecting many milestone and we want to give you and update on our progress. First, we have changed our communication focus, and will talk about different themes that are related to the success of Cessatech. The first being Working Smart, as Repurposing and Collaborations are fundamental to our aspirations. The second is obviously our Pipeline. The rest will come in our business updates to come...

## Working Smart. Repurposing and Collaborations

In 2022 we expanded the team preparing us for the further development of our pipeline, as well as our future plans, which is very much all about partnerships both for the development of CT001 and later potential commercialisation. Our partnerships shortens the time to market and reduce risk. We select them carefully, and spend much effort and time on making the collaborations work. It can at times be hard work, but also extremely rewarding when it really goes well. As a company we are much more flexible and close to expert input.



We recently welcomed **Helle Sickmann Bendixen**, as Head of Clinical Development and Operations and **Martin Juhl**, as Head of CMC and Device. Both with extensive experience and a true asset to Cessatech.

We also welcomed **Rachel Gravesen** to the Board of Directors – Rachael has an extensive experience from Genmab and Novo Nordisk working with Communication and IR. All her input is highly appreciated.

LEAD ASSET CT001:  
AT LATE-STAGE DEVELOPMENT

## Pipeline update

During 2022 we advanced the development of our nasal spray (CT001) for acute pain in children:



**Successful outcome of phase 2 pharmacokinetics trial (0206) in children** undergoing elective surgical procedures, thus demonstrating that CT001 nasal spray is feasible as premedication in children undergoing anaesthesia.



**Further the first patient was dosed in pivotal trial (0205) in adult patients** – this trial investigates the postoperative analgesic efficacy of CT001.

[Find out more](#)

## Financials – ready for 2023.

### ACTUALITY

Cessatech is entering 2023 with a good cash position – further extended by a successful execution of the rights issue in Q4 2022 raising approximately DKK 14,7 mill before transaction costs.

### WHAT'S NEXT?

In 2023 we plan to further advance of our pipeline with a focus on our nasal spray (CT001) for acute pain in children. We expect top-line results of the 0205 trial and hopefully a commercial partnership collaboration.

Income Statement ('000)	Q4'21	Q1'22	Q2'22	Q3'22	Balance sheet ('000)	Q4'21	Q1'22	Q2'22	Q3'22
Operating expenses	3.426	2.205	2.473	2.297	Assets	30.653	24.648	22.323	20.047
Staff expenses	972	1.531	1.467	955	Cash	3.275	21.204	17.846	15.001
Loss before tax	4.402	3.811	3.994	3.292	Equity	26.242	23.392	20.228	17.744
Net loss	3.594	3.045	3.319	3.319	Solidity rate	86%	95%	91%	89%

## Cessatech management team



Jes Trygved  
CEO



Helle Sickmann Bendixen  
CLINICAL



Martin Juhl  
CMC & DEVICE




Louise Bak  
REGULATORY LEAD

## Shareholders

Management, Board of Directors and other Insiders.

Currently hold 16%



	Use	Indication	Pre-clinical	Phase I	Phase II	Pivotal - Ph III
CT001 Fixed combination	Non-invasive nasal spray	Acute pain	CT001			
CT002 Sedative-analgesic	Non-invasive nasal spray	Sedation	CT002			
CT003 Local analgesia	Local gel	Topical anaesthesia	CT003			

### THERE IS AN UNMET NEED FOR PAIN TREATMENT OF CHILDREN.

Studies show that of label use of medication is the rule rather than the exception and that 79% of the emergency rooms in Scandinavia use physical restraint on children.

Cessatech aims to meet that need – and the first product and lead asset, CT001, is a nasal spray for children aged 1–17 years that experience acute pain or pain related to medical procedures.

Drugs that are developed by Cessatech should be proven effective in adults and represent a medical unmet need in children where a good effect can be documented. Thus offering economic value creation by identifying and developing drugs with a short time to market and risk-reduced profile.

